TY - JOUR
T1 - Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))
AU - Olawaiye, Alexander B.
AU - Java, James J.
AU - Krivak, Thomas C.
AU - Friedlander, Michael
AU - Mutch, David G.
AU - Glaser, Gretchen
AU - Geller, Melissa
AU - O'Malley, David M.
AU - Wenham, Robert M.
AU - Lee, Roger B.
AU - Bodurka, Diane C.
AU - Herzog, Thomas J.
AU - Bookman, Michael A.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/1
Y1 - 2019/1
N2 - The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85055083698&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2018.10.022
DO - 10.1016/j.ygyno.2018.10.022
M3 - Comment/debate
C2 - 30360899
AN - SCOPUS:85055083698
SN - 0090-8258
VL - 152
SP - 220
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -